iRhythm Technologies, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- iRhythm Technologies, Inc. iRhythm Technologies, Inc. (IRTC) is a leading digital healthcare company that develops and commercializes wearable biosensors and cloud-based platforms focused on cardiac arrhythmia detection and prediction. The company offers a comprehensive suite of ambulatory cardiac monitoring solutions through its Zio platform, including the Zio monitor for long-term continuous ECG monitoring up to 14 days, Zio XT for extended wear applications, Zio AT for real-time event monitoring without battery changes, and the recently submitted Zio MCT next-generation mobile cardiac telemetry device featuring a smaller form factor, 21-day wear period, and advanced detection algorithms; these services integrate AI-powered analytics verified by qualified cardiac technicians, patient symptom logging via the MyZio mobile app, and ZioSuite data management for physicians, achieving high diagnostic yield, 99% physician agreement on reports, and superior clinical outcomes compared to shorter-duration monitors. iRhythm Technologies, Inc. primarily serves cardiologists, primary care providers, and health systems in the United States, with expanding operations in Europe, the United Kingdom, Japan, and the Philippines from its headquarters at 699 8th Street, Suite 600, San Francisco, California, where it was founded in 2006. In recent developments, the company formed a strategic AI partnership with Lucem Health to enable early arrhythmia detection in high-risk populations such as those with type 2 diabetes, chronic kidney disease, COPD, and coronary artery disease; launched Zio long-term continuous monitoring services in Japan; reported record Q3 2025 revenue of $192.9 million, up 30.7% year-over-year, with raised full-year guidance to $735-740 million; published significant real-world studies in Heart Rhythm validating Zio performance and presented findings at AHA Scientific Sessions 2025 and other conferences demonstrating advantages in arrhythmia yield and healthcare cost reduction; and submitted a 510(k) filing to the FDA for Zio MCT while expanding value-based care partnerships across 18 active accounts.
iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform
Here's Why iRhythm Holdings, Inc. (IRTC) is a Strong Momentum Stock
iRhythm Technologies $IRTC Shares Sold by Bank of America Corp DE
iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
iRhythm Combines Strong Performance with VitalConnect Buy to Expand Remote Cardiac Care
iRhythm Holdings, Inc. (IRTC) Q2 2026 Earnings Call Transcript
iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimates
iRhythm Technologies Q2 Earnings Call Highlights
iRhythm Holdings Announces Second Quarter 2026 Financial Results
Bernstein Litowitz Berger & Grossmann LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of iRhythm Technologies, Inc. Common Stock
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
Castleark Management LLC Sells 23,000 Shares of iRhythm Technologies $IRTC
iRhythm Technologies $IRTC Shares Sold by Bessemer Group Inc.
iRhythm Holdings to Report Second Quarter 2026 Financial Results on August 6, 2026
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm